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Caseinophosphopeptides (CPP) were detected for the first time in ileostomy fluid, collected at
2 h intervals for 10 h post milk and CPP ingestion, from human volunteers with an ileostomy.
The level of CPP present in ileostomy fluid obtained from milk-fed volunteers was markedly
higher than that from volunteers fed with selected CPP preparations. The findings are based
on HPLC analysis in combination with peptide-bound P determination, thin-layer electropho-
resis and amino acid analysis, together with ELISA studies using polyclonal antibodies
raised against a set of CPP to detect immunoreactive CPP in ileostomy fluid. These procedures
allowed the detection of nM concentrations of CPP. CPP, which can be released during
intestinal digestion, may function as bioactive constituents and carriers for different minerals,
especially Ca, and may be used as ingredients in functional foods or pharmaceutical
preparations.
Caseinophosphopeptides: Milk: Human ileostomy samples: Bioactive peptides
Food-derived bioactive peptides represent a source of
health-enhancing components that may be incorporated
in functional foods and in pharmaceutical preparations.
These peptides are potential modulators of various regulat-
ory processes in the body. Milk proteins are precursors
of many different biologically active peptides, e.g. pep-
tides having opioid, hypotensive (angiotensin-converting
enzyme inhibitory), immunomodulating or antimicrobial
activities (for reviews, see Meisel, 1997, 2001; FitzGerald
& Meisel, 2000; Meisel & FitzGerald, 2000). The intrinsic
bioactivities of the peptides encrypted in major milk pro-
teins are latent until they are released and activated by
enzymatic hydrolysis, e.g. during gastrointestinal digestion
and/or food processing. Several studies have been per-
formed in the last two decades on caseinophosphopeptides
(CPP), which may function as carriers for different
minerals, especially Ca (for review, see FitzGerald,
1998). It has been proposed that CPP, which form soluble
complexes with Ca3(PO4)2 in vitro, may lead to enhanced
Ca absorption by limiting the precipitation of Ca at alka-
line conditions pertaining in the distal ileum. However,
until now it had not been established whether CPP can
be obtained in the human ileum following digestion of a
milk meal (Meisel et al. 2001). For their function as min-
eral carriers CPP must, at least partially, resist enzymatic
digestion during intestinal passage. In the present study
(see also Meisel et al. 2001), intestinal fluid samples
obtained from human subjects during feeding trials with
milk and selected CPP preparations were analysed for the
presence of CPP.
Material and methods
Milk and caseinophosphopeptide preparations
The same brand of a fresh pasteurized, homogenized full-fat
cows’ milk was obtained from a local food retailer for the
duration of the present study. CPP were generated as pre-
viously described (McDonagh & FitzGerald, 1998) from
bovine sodium caseinate, which was hydrolysed with four
different commercially available food-grade proteinase
preparations, i.e. PTN 3·0S and Alcalase (both obtained
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from Novo Nordisk, Novo Alle, Bagsvaerd, Denmark),
Bioprotease P(conc) (Quest International, Carrigaline,
Cork, Republic of Ireland) and Proteinase DS (Rhoˆne-
Poulenc, Stockport, Cheshire, UK), resulting in CPP
preparations designated CPP1, CPP2, CPP3 and CPP4
respectively. CPP were aggregated by inclusion of Ca
(Adamson & Reynolds, 1995) and the resultant aggregates
were collected by ultrafiltration through 10 kDa cut-off
membranes (Brule, 1982; McDonagh & FitzGerald, 1998).
The CPP preparations were decalcified (McDonagh &
FitzGerald, 1998) prior to spray-drying. The N:P for these
different preparations were: 3·11:1·00, 3·15:1·00, 4·0:1·00,
and 3·59:1·00 respectively. All four preparations had
.90 % peptide materials with a molecular mass ,1 kDa.
Ileostomy study
One male and three female volunteers with an ileostomy par-
ticipated in the present study. The mean age of the volunteers
was 51·5 (SD 7·9) years. All four volunteers were without any
acute digestive problems and were taking routine antacid
medication to help digestion; no medication was taken
during the experimental days. The study protocol was
approved by the Norfolk (UK) District Ethics Committee
and informed consent was obtained from each volunteer
prior to participation. Volunteers were chosen on the basis
that they had no prior history of adverse reactions to the
consumption of milk proteins. Cytochemical assessment of
CPP in vitro (Caco-2 cells) revealed no cytotoxic potential,
and no adverse influence on epithelial properties and differ-
entiation (Hartmann & Meisel, 2002).
In the present study, which was carried out within 2
months, each volunteer consumed either 250 g full-fat
cows’ milk or one of four different CPP preparations
(1·52 g in 20 ml water), together with a standard milk-pro-
tein-free breakfast, on two separate occasions following an
overnight fast. Ileostomy fluid was collected at baseline
(t 0) after a 10 h overnight fast and following the test
meal in 2 h intervals for 10 h (t 1–5). The two tests were
separated by at least 2 weeks. To avoid consumption of
milk products, volunteers were provided with a diet free
of milk protein for 2 d prior to both test days. During the
10 h experimental period, volunteers were confined to the
premises of the Human Nutrition Unit at the Institute of
Food Research (Norwich, Norfolk, UK). The same
milk-protein-free lunch was provided for all volunteers
throughout the study. Ileostomy fluid was immediately
centrifuged at 5000 g for 10 min at 48C after collection
and the pellet and supernatant fractions were stored at
2188C prior to freeze-drying. According to the volunteer
and the meal ingested, the ileostomy samples were desig-
nated as 01-1:CPP2, 01-2:Milk, 02-1:CPP4, 02-2:Milk,
03-1:Milk, 03-2:CPP1, 04-1:Milk, 04-2:CPP3.
Extraction of ileostomy samples
Addition of perchloric acid prevented the degradation of
CPP by proteolytic and/or peptideolytic action in reconsti-
tuted ileostomy samples, presumably by inhibition of
enzymes of intracellular or bacterial origin, which may be
liberated after freezing and thawing (D McDonagh,
H Meisel, C Lane and RJ FitzGerald, unpublished obser-
vations). Lyophilized ileostomy sample (100 mg) was
suspended in 2 ml perchloric acid (172 mM, pH 1·2 in the
final extract). The suspension was vortexed vigorously for
1 min and then treated in an ultrasonic bath for 3 min.
After centrifugation at 14 000 g for 3 min, the perchloric
acid-soluble portion of ileostomy samples was used for
further analyses. Ileostomy samples, which had been col-
lected at various time intervals (t 1–5), were pooled for
analysis of CPP in order to maximize the likelihood of
detecting CPP.
Adsorptive microconcentration
Microcon strong cation exchange (SCX) units (Amicon,
Inc., Beverly, MA, USA) containing a SCX membrane
were used for adsorptive microconcentration of phospho-
peptides. The manufacturer’s protocol was followed with
minor modifications. To wet the membrane, 0·5 ml metha-
nol and then 0·5 ml water were centrifuged at 7000 g for
15 s through the SCX unit. Sample ð4 £ 0·5 mlÞ was
loaded into the SCX unit. The filtrate (SCX-A) obtained
after centrifugation at 1200 g for 10–30 min was collected
for further analyses. Thereafter, the membrane was washed
with 10 mM-HCl to remove residual contaminants. For
elution of adsorbed peptides, 50ml desorption reagent
(0·5 ml methanol, 0·1 ml NH3 (250 ml/l), 0·4 ml water)
was pipetted into the unit and was then centrifuged at
14 000 g for 1 min; this step was repeated once and the
respective filtrates (microconcentrate SCX-B) were com-
bined for further analyses.
Analytical and semi-preparative reverse-phase HPLC
The reverse-phase HPLC-system consisted of two 422
Master pumps (Bio-Tek Kontron, Neufahrn, Germany),
two mixers M800 (Bio-Tek Kontron), injector 7125 (Rheo-
dyne, Rohnert Park, CA, USA), column oven (constructed
by the authors), diode array detector 440 (Bio-Tek Kon-
tron), Foxy fraction collector (ISCO, Lincoln, NE, USA)
and data system KromaSystem 2000 (Bio-Tek Kontron).
A LiChroCART Supersphere 100 C18 endcapped 124 £
4 mm column (16855; Merck, Darmstadt, Germany) was
used for analytical and semi-preparative separations;
column temperature was 308C. Solvent A was trifluoroace-
tic acid (1 ml/l water) and solvent B was trifluoroacetic
acid (1 ml/l aqueous acetonitrile (500 ml/l)). Both solvents
were purged with He. Freeze-dried samples were taken up
in eluent A. Sample solutions (100ml extracted material
from 100 mg freeze-dried powder reconstituted in 2 ml
perchloric acid) were injected and eluted at a flow rate of
1 ml/min. The gradient used was 50 ml B/l for 5 min and
50–900 ml B/l in 85 min. For rechromatography, a shal-
lower gradient (50 ml B/l for 5 min and 50 to 450 ml B/l
in 80 min) was used. Peaks were detected by absorbance
at 215, 235 and 280 nm. Peptide fractions were collected
and solvents were removed by freeze-drying (Speed Vac
concentrator; Savant, Holbrook, NY, USA).
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Determination of phosphorus content
P content was measured after wet ashing of freeze-dried
samples, which converts organic P to inorganic phosphate.
Inorganic phosphate was quantified as the phosphomoly-
bdate complex by an ultramicro method (Meisel & Frister,
1988).
Amino acid analysis
Freeze-dried samples were hydrolysed with 6 M-HCl–
phenol (10 ml/l) in evacuated tubes at 1108C for 24 h.
Amino acid analysis was performed with an Alpha Plus ana-
lyser (type 4151; Amersham Pharmacia Biotech, Freiburg,
Germany) using an Ultrapac 8 ion-exchange resin (80-
202845; Amersham Pharmacia Biotech) and sodium citrate
buffer system (Amersham Pharmacia Biotech). SerP content
per mg lyophilized ileostomy sample was obtained by extra-
polation of the SerP concentration in acidic hydrolysates
(6, 12, 24 h) to zero time. Calibration was achieved by
running a mixture of standard amino acids (AA-S18;
Sigma, St Louis, MO, USA) and SerP (Sigma) respectively.
Thin-layer electrophoresis
Thin-layer electrophoresis was performed using a thin-layer
electrophoresis double chamber connected to a mains
supply unit 1200/200 (DESAGA, Heidelberg, Germany).
Samples (5–10ml) of acidic hydrolysates (t 3) of ileostomy
samples were dotted on microcrystalline cellulose sheets
(Polygram CEL 400, 0·20 £ 0·20 m; 0·1 mm thickness;
Macherey-Nagel, Du¨ren, Germany); an additional set of
the same samples were spiked with a SerP solution
(5 nmol/0·5ml water). Separations were carried out in
pyridine–acetic acid–water (5:50:945, by vol.), pH 3·5,
at 400 V/15–20 mA for 1 h. Components of the partial
hydrolysates were detected by spraying with a solution of
ninhydrin (0·1 mg/50 ml methanol) and heating for 5 min at
1108C.
Preparation and purification of a synthetic phosphopeptide
A consensus phosphopeptide with a sequence of VESLSS
SEESIL (S depicts SerP residues) was synthesized using a
Milligen 9050 apparatus (Biosearch Inc., Novato, CA,
USA) and standard solid-phase synthesis by the 9-fluore-
nylmethoxycarbonyl continuous-flow method. Synthetic
peptide was purified by successive anion-exchange chro-
matography using a fast protein liquid chromatography
system with a mono Q HR 10/10 column (Amersham Phar-
macia Biotech), and reverse-phase HPLC using a Waters
system (Milford, MA, USA) and a 300 A C18 Vydac
column (250 £ 10 mm; Shandon, France).
Immunogen preparation
Tryptic CPP isolated by Ca2+–ethanol precipitation from
whole casein were coupled to keyhole lympet (megatura
crenulata) haemocyanin via its amino groups, using glutar-
aldehyde. Briefly, 5 mg CPP and 20ml glutaraldehyde were
successively added to 10 mg keyhole lympet haemocyanin
dissolved in 10 ml 0·1 M-phosphate buffer, pH 7·4. After
18 h stirring at 48C, the mixture was divided into 1 ml por-
tions and stored at 2208C.
Immunization
Anti-whole CPP antisera was obtained by immunizing adult
male white Blanc-de Bouscat rabbits as follows: 1 ml immu-
nogen solution (250 ml/l water) was emulsified with 1 ml
Freund’s complete adjuvant and injected subcutaneously
into two rabbits (no. 1494 and no. 1495). Booster injections
were given 6 weeks later and once per month thereafter.
Rabbits were bled 10 d after each immunization. Sera
were stored at 48C after addition of sodium azide (0·1 g/l).
Enzymatic tracer preparation
Enzymatic tracer was prepared by covalent linkage of
consensus synthetic phosphopeptide to the tetrameric
form of acetylcholinesterase. This method involved the
reaction of thiol groups introduced into phosphopeptide
using N-succinimidyl-S-acetyl-thioacetate with maleimido
groups previously incorporated into acetylcholinesterase
with N-succinimidyl-4-(maleido-methyl)-cyclohexane-1-
carboxylate as previously described (Caruelle et al. 1988).
Competitive enzyme immunoassay
All the dilutions were performed in enzyme immunoassay
(EIA) buffer corresponding to 0·1 M-potassium phosphate
pH 7·4, containing 0·15 mol NaCl/l, 1 g bovine serum albu-
min/l and 0·1 g sodium azide/l. Competitive EIA were per-
formed using ninety-six-well microtitre plates coated with
mouse monoclonal anti-rabbit immunoglobulin G (10mg/
ml 50 mM-phosphate buffer, pH 7·4 for 18 h at 48C
before saturating with EIA buffer), in order to ensure sep-
aration of bound and free moieties of the enzymatic tracer
during the immunological reaction. The total volume of the
immunological reaction was 150ml, each component
(enzymatic tracer, rabbit polyclonal antisera and standard
or sample) being added in a volume of 50ml. The enzy-
matic tracers were used at a concentration of 2 Ellman
units/ml (Ellman et al. 1961), while the working dilutions
for the corresponding rabbit antisera were previously deter-
mined by serial dilution experiments. After 4 h incubation
at 208C, the plates were washed (with 0·01 M-phosphate
buffer pH 7·4 containing 0·5 ml Tween 20/l) before the
enzyme activity of the bound immunological complex
was quantitated by addition of 200ml Ellman’s reagent
(7·5 £ 1024 M acetylthiocholine iodide, substrate; 5 £
1024 M 5,50-dithiobis(2-nitrobenzoic acid), reagent for
thiol colorimetric measurement) per well. After 1 or 2 h
of gentle shaking in the dark at room temperature, the
absorbance of each well at 414 nm was measured using
an automatic plate reader. Results were expressed in
terms of B/B0 (%) as a function of the dose (logarithmic
scale), where B and B0 represent the bound activity in
the presence or absence of competitor respectively. All
measurements for standards or samples were made in
duplicate, and in quadruplicate for B0 values. A linear
log–logit transformation was used to fit the standard
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curve. The assay sensitivity was characterized by the dose
of standard inducing a 50 % reduction of the binding
observed in absence of competitor (B/B0 50 %). The mini-
mum detectable concentration corresponds to an 80 %
reduction of the binding (B/B0 80 %).
Results
(Phospho)peptide pattern of human ileostomy fluid
The peptide profiles of ileostomy extract samples pooled
over the time points t 1–5 were quite similar between
one subject and another (four volunteers with an ileos-
tomy), and were largely independent of the test meal
ingested, i.e. milk or CPP (Fig. 1). From the HPLC profiles
of the different ileostomy fluid samples, no distinctive pep-
tide could be assigned to a component or digestion product
of the ingested milk and CPP preparations. The chromato-
grams measured in the fasting state (t 0) also revealed com-
plex but different patterns (results not shown) as compared
with those that were obtained 2 to 10 h post-dose (t 1–5).
Using HPLC analysis in combination with the determi-
nation of organically bound P, CPP were found in the
perchloric acid-soluble peptide fraction of ileostomy
samples obtained from volunteers who ingested milk
(Fig. 2, Table 1). However, no CPP were detected in ileos-
tomy samples of volunteers fed specific CPP preparations or
in pre-meal samples collected before ingestion of a test meal
(t 0). This observation also pertained even if adsorptive
(SCX) microconcentration was applied as an additional
D
et
ec
to
r 
re
sp
o
n
se
 (
m
V
) 
at
 2
15
 n
m
0
200
400
600
800
1000
Time (min)
0 15 30 45 60 75 90
Time (min)
0 15 30 45 60 75 90
0
200
400
600
800
1000
(A)
(B)
Fig. 1. HPLC peptide patterns of ileostomy fluids collected for 10 h post-dose at 2 h intervals (pooled over the time points t 1–5) from four
human volunteers after ingestion of a milk meal (A) and caseinphosphopeptides (CPP) meal (B). Test sample reverse-phase HPLC profiles
were overlaid for direct comparison purposes. The magnitude of the detector response for all samples was similar. For details of subjects
and test meals, see p. 352. (A), patterns represent (vertically, from top) 01-2:Milk, 02-2:Milk, 03-1:Milk, 04-1:Milk; (B), 01-1:CPP2, 02-1:CPP4,
03-2:CPP1, 04-2:CPP3 (for details of sample classification, see p. 352).
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step to enrich for CPP. In earlier experiments, adsorptive
microconcentration (SCX) enabled the enrichment of CPP
from ileostomy extract spiked with pure phosphopeptides.
Non-phosphorylated peptides were also enriched to some
extent, but the concentration of CPP (measured by peak
area) was more than 7-fold greater in the corresponding
microconcentrate. Therefore, the use of adsorptive micro-
concentration for the enrichment of CPP from intestinal
chyme may compensate for the 3- to 5-fold dilution of the
meal within the intestine (Borgstro¨m, 1957).
The results from HPLC analysis showing the presence of
CPP in ileostomy fluid were confirmed by thin-layer electro-
phoresis as a specific qualitative method to detect SerP in
hydrolysates of ileostomy samples as well as by quantitative
amino acid analysis to measure the SerP content (Table 1).
The composition of the CPP in intestinal fluid changed
with time post-dose following ingestion of milk (Fig. 3),
and the amount of CPP decreased after prolonged digestion
($8 h). An increase in total peak area and number of peaks
after more than 6 h (e.g. t 4 in Fig. 3) may be due to diges-
tion of lunch, which was taken 3 h after ingestion of the
meals (milk or CPP preparation).
Immunoreactive caseinophosphopeptides in human
ileostomy fluid
The EIA system has been developed using specific rabbit
polyclonal antibodies raised against a mixture of CPP
prepared by tryptic hydrolysis of whole casein and an
acetylcholinesterase-labelled synthetic phosphopeptide.
This test system appears to be sensitive, allowing a range
of detection between 1 and 10 nmol/ml depending on the
polyclonal antibodies used. The binding of acetylcholin-
esterase-labelled synthetic phosphopeptide to rabbit anti-
bodies was easily inhibited by CPP preparations, e.g.
CPP1, 2, 3 and 4, which presented similar inhibition
values. Moreover, no differences were observed in the inhi-
bition curves between CPP preparations with or without per-
chloric acid extraction. The EIA system was then applied to
detection of CPP in ileostomy samples (Fig. 4). The validity
of the competitive EIA system was supported by the very
good agreement in the results obtained with anti-CPP anti-
bodies obtained from two animals (rabbits no. 1494 and
no. 1495). Pre-meal (t 0) ileostomy extract samples dis-
played some low inhibitory effects at a 1:5 dilution, which
disappeared at a 1:25 dilution. However, as shown in
Fig. 4, extracts from ileostomy samples pooled over the
time points from human subjects fed either milk or CPP
preparations markedly inhibited the binding even at a
dilution greater than 1:625. In agreement with results from
HPLC and thin-layer electrophoresis analyses (Table 1),
greater inhibition (at least a 100-fold difference) was
observed for ileostomy samples obtained from human sub-
jects fed milk as opposed to CPP.
Discussion
The reverse-phase HPLC peptide patterns (samples pooled
over the time points t 1–5) were not characteristic of the
test meal ingested, and complex elution profiles were
also obtained in the fasting state (t 0). Therefore, it
would appear that the reverse-phase HPLC profiles also
contained many endogenous components secreted into the
intestinal fluid.
CPP were detected in ileostomy fluid obtained from
human volunteers using two separate approaches, i.e.
using HPLC analysis (in combination with peptide-bound
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Fig. 2. HPLC peptide pattern and P content of ileostomy fluid (per-
chloric acid-soluble fraction) collected for 10 h post-dose at 2 h inter-
vals (pooled over the time points t 1–5) from four human volunteers
after ingestion of a milk meal. Elution of inorganic P in fractions 1–5,
organic (peptide-bound) in fractions .5. For details of subjects and
test meals, see p. 352. (A), 01-2:Milk; (B), 02-2:Milk; (C), 03-1:Milk;
(D), 04-1:Milk (for details of sample classification, see p. 352).
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P and SerP determination) of ileostomy extract, as well as
the application of a unique EIA system. Both the immuno-
chemical and chromatographic–peptide chemical approach
to detect CPP enabled the semi-quantification of CPP in
human ileostomy fluid of milk-fed volunteers (Table 1).
However, the quantity of CPP in ileostomy samples from
volunteers fed with CPP preparations was too small to be
detected by HPLC or SerP analyses. The EIA system com-
bined a broad specificity suitable for the detection of
numerous different phosphopeptides and a high sensitivity
that allows detection of trace amounts in complex media
such as in biological fluids or food matrices.
The reason for looking at CPP generated with four differ-
ent proteolytic preparations was that there were differences
in the Ca2+ binding and solubilizing abilities of CPP in vitro
depending on the enzyme preparation used in hydrolysate
generation (McDonagh & FitzGerald, 1998). However,
this has not proved to be relevant in the current in vivo
study. There is obviously an effect of the food matrix
that protects CPP from degradation in the gut, provided
that they are ingested as milk constituents and not as
isolated CPP ingredients. CPP are not found naturally in
good quality milk, but are encrypted in the primary struc-
ture of the caseins and are released by proteolytic action.
Therefore, the form in which phosphopeptides exist in
milk v. that in which they exist in the CPP meal is quite
different, and this may account for potential differences in
proteolytic susceptibility during gastrointestinal transit. It
is worth noting that CPP released during milk digestion
appeared to be stable for up to 8 h in ileostomy contents
(Fig. 3). Milk seems to be a good ‘wrapping’ or ‘carrier’
for CPP, i.e. the corresponding protein-bound sequences
are partly protected against proteolytic attack.
Based on the fact that the ingested amount of milk (250 g)
is equivalent to 6·5 g casein, which accounts for 55 mg
(1·775 mmol) organically bound P (Po; Douglas et al.
1982), a maximal recovery of 15 % peptide-bound P for
the digestion products of milk can be estimated from the
content of peptide-bound SerP (Table 1) multiplied by the
total weight of freeze-dried ileostomy samples. Casein
theoretically yields 126 mg CPP/g, which is released predo-
minantly during tryptic in vitro proteolysis (Meisel, 1998).
This would suggest that about 120 mg potentially available
CPP could be liberated into the ileum after a meal of 250 g
milk. This estimation is supported by an alternative calcu-
lation, which assumes that the CPP in ileostomy fluid
have predominantly two SerP groups and that their average
relative molecular mass was 1000.
The Ca-binding constants for different CPP preparations
are reported to be in the order of 102–103 l/mol (Berrocal
et al. 1989; Sato et al. 1991; Meisel & Olieman, 1998).
Interestingly, the amount of Ca solubilized per mol CPP is
far in excess of the estimated amount of SerP that binds an
almost equivalent number of Ca2+. Accordingly, Berrocal
et al. (1989) estimated that the effective CPP concentration
required to inhibit the formation of insoluble Ca3(PO4)2 in
vitro was 10 mg/l. Furthermore, it has been shown that rela-
tively low concentrations of CPP (10–50 mg/l) can stimu-
late cultivated immunocompetent human cells (Hata et al.
1998, 1999). Therefore, it is postulated that the quantity
of CPP found in ileostomy fluid in the present study could
be of physiological importance.
Table 1. Identification of phosphopeptides in pooled ileostomy fluid collected for 10 h at 2 h intervals (t 1–5) after ingestion of a test meal*
Peptide-bound P (HPLC)‡ Peptide-bound SerP
Immunoreactive CPP
(EIA; nmol/mg){Ileostomy sample† nmol/fraction Fraction no. TLE (ninhydrin-positive spot)§ AAA (nmol/mg)k
Subject 1
01-01:CPP2 nd nd nd nd 0·05
01-02:Milk 8 12–14 + 7·3 7·10
36 26–32
Subject 2
02-01:CPP4 nd nd nd nd 0·09
02-02:Milk 15 5–8 + 4·8 4·40
11 12–15
3 21
18 27–30
Subject 3
03-01:Milk 7 28–29 + 3·1 2·60
03-02:CPP1 nd nd nd nd 0·02
Subject 4
04-01:Milk nd nd + 2·8 2·60
04-02:CPP3 nd nd nd nd 0·02
Pre-meal** nd nd nd nd ,0·002
TLE, thin-layer electrophoresis; SerP, phosphoserine; AAA, amino acid analysis; EIA, enzyme immunoassay; CPP, caseinophosphopetide; nd, not detected.
* For details of subjects and test meals, see p. 352.
† The soluble fraction obtained after extraction with perchloric acid (172 mM) was analysed. For details, see p. 352.
‡ HPLC analysis and determination of total organically bound P in HPLC fractions.
§ TLE of partial acid hydrolysates (6 h) and ninhydrin-positive spot of SerP.
kAAA of acidic hydrolysates (6, 12, 24 h). SerP content per mg lyophilized ileostomy sample was obtained by extrapolation to zero time; non-hydrolysable material
having the same elution position as SerP (equivalent to #0·5 nmol/mg) was present in all samples; SerP was not detectable in the insoluble part of extracted
ileostomy samples.
{Competitive EIA using rabbit (no. 1495) polyclonal antiserum and acetylcholinesterase-labelled synthetic phosphopeptide as tracer. CPP concentration equival-
ent to the amount of synthetic VESLSSSEESIL ðS ¼ SerPÞ per mg lyophilized ileostomy sample.
** The pre-meal sample represents a pool of all samples collected in the fasting state (t 0).
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The in vivo formation of CPP derived from bovine casein
was demonstrated in the small intestinal fluid of minipigs
after ingestion of a diet containing casein (Meisel & Frister,
1988). Chabance et al. (1998) recently detected CPP in the
stomach and duodenum of adult human subjects after
ingestion of milk or yogurt. Our present studies demon-
strate, for the first time, that phosphopeptides can survive
the prolonged intestinal passage to the distal small intestine
(ileum) in vivo, which is a prerequisite for their function as
bioactive substances. Vitamin D-independent paracellular
transport of Ca is known to play a major role in maximal
passive Ca absorption from the distal small intestine
(Bronner, 1987). However, the physiological significance
of CPP as potentially bioactive substances in the ileum
has not yet been clarified. Preliminary results indicate
that consumption of CPP by human subjects does
not significantly increase the fractional absorption of
dietary Ca (B Teucher, G Majsak-Newman, JR Dainty,
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Fig. 3. HPLC peptide patterns and P content of ileostomy fluids
(perchloric acid-soluble fraction) measured at different time points
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Fig. 4. Inhibition of the binding of specific rabbit anti-caseino-
phosphopeptides (CPP) antibodies (A, rabbit no. 1494; B, rabbit
no. 1495) to synthetic phosphopeptide VESLSSSEESIL-acetylchol-
inesterase, where S is phosphoserine) by different ileostomy
samples from four human volunteers after ingestion of a milk meal
(S 01-2:Milk; W 02-2:Milk; A 03-1:Milk; K 04-1:Milk) and CPP
meal (V 01-1:CPP2;† 02-1:CPP4; B 03-2:CPP1; O 04-2:CPP3).
The y-axis represents the bound enzyme activity in presence (B)
or absence (B0) of competitor. For details of subjects and pro-
cedures, see p. 352.
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D McDonagh and S Fairweather-Tait, unpublished obser-
vations). Nevertheless, it has recently been demonstrated
that CPP mediate Ca uptake in rat intestinal everted
sacs (Erba et al. 2001) and into epithelial (HT29) cells
(Ferraretto et al. 2001). Furthermore, the production of
immunoglobulin G was stimulated by CPP in immuno-
competent human cells (Hartmann et al. 2000). The latter
finding is in support of the suggestion (Hata et al. 1998;
Otani et al. 2000) that CPP may act as immunostimulators,
which are beneficial to the enhancement of mucosal immu-
nity. Therefore, irrespective of their possible function as Ca
carriers, CPP are of particular interest as dietary com-
ponents that may modulate specific bodily functions and
thus have functional food ingredient potential for promot-
ing better health and reducing the risk of developing
specific diseases.
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